Lowest Price Guaranteed
Pages
403
Last Updated
August 2026
View Count
5582
1. PREFACE
1.1. Introduction
1.2. Report Coverage
1.3. Market Segmentation
1.4. Key Market Insights
1.5. Market Share Insights
1.6. Key Questions Answered
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Asia-Pacific Liquid Biopsy Solutions: Market Landscape
5.2. Asia-Pacific Liquid Biopsy Solutions: Market Trends
5.3. Asia-Pacific Liquid Biopsy Solutions: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Cancer Statistics and Burden of the Disease
6.3. Importance of Early Cancer Detection
6.4. Cancer Screening and Diagnosis
6.5. Conventional Invasive Cancer Diagnostic Tests
6.5.1. Biopsy
6.5.2. Fine Needle Aspiration Biopsy
6.5.3. Core Needle Aspiration Biopsy
6.5.4. Vacuum-Assisted Biopsy
6.5.5. Image Guided Biopsy
6.5.6. Sentinel Node Biopsy
6.5.7. Surgical Biopsy
6.5.8. Endoscopic Biopsy
6.5.9. Bone Marrow Biopsy
6.5.10. Endoscopy
6.6. Need for Non-Invasive Approaches
6.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
6.7.1. Circulating Tumor Cells
6.7.2. Circulating Tumor DNA / Cell Free DNA
6.7.3. Exosomes
6.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
6.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
6.10. Challenges Associated with Non-Invasive Cancer Diagnostics
6.11. Future Perspectives
7. CASE-STUDY: NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
7.1. Chapter Overview
7.2. Diagnostic Imaging
7.2.1. Magnetic Resonance Imaging (MRI)
7.2.2. Mammography
7.2.3. Bone Scan
7.2.4. Computerized Tomography (CT) Scan
7.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
7.2.6. Ultrasound
7.2.7. X-ray Radiography (Barium Enema)
7.3. Screening Assays
7.3.1. Circulating Tumor Marker Test
7.3.2. Digital Rectal Exam (DRE)
7.3.3. Fecal Occult Blood Test (FOBT)
7.3.4. Multigated Acquisition (MUGA) Scan
7.3.5. Papanicolaou Test and Human Papilloma Virus Test
7.4. Advanced Non-Invasive Approaches
7.4.1. Cytogenetic / Gene Expression Studies
7.4.2. Molecular Signature-based Non-Invasive Methods
7.4.3. Saliva-based Oral Cancer Diagnostics
7.4.4. Vital Staining
7.4.5. Optical Biopsy
7.4.6. Other Diagnostic Techniques
8. MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Asia-Pacific Liquid Biopsy Solutions: Overall Market Landscape
8.2.1. Analysis by Stage of Development
8.2.2. Analysis by Type of Solution
8.2.3. Analysis by Type of Technology
8.2.4. Analysis by Type of Sample
8.2.5. Analysis by Type of Circulating Biomarker
8.2.6. Analysis by Type of Cancer
8.2.7. Analysis by Solution Purpose
8.2.8. Analysis by Application Area
8.3. Asia-Pacific Liquid Biopsy Market: Overall Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Analysis by Most Active Players
9. PRODUCT COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Overview of Peer Groups
9.4.1. Peer Group I: Overview of Liquid Biopsy Assay Kits
9.4.2. Peer Group II: Overview of Liquid Biopsy Devices
9.4.3. Peer Group III: Overview of Liquid Biopsy Software and Other Solutions
9.5. Product Competitiveness Analysis
9.5.1. Liquid Biopsy Assay Kits
9.5.2. Liquid Biopsy Devices
9.5.3. Liquid Biopsy Software and Other Solutions
10. COMPANY PROFILES: ASIA-PACIFIC LIQUID BIOPSY SOLUTION PROVIDERS
10.1. Chapter Overview
10.2. Amoy Diagnostics
10.2.1. Company Overview
10.2.2. Liquid Biopsy Portfolio
10.3. Gencurix
10.3.1. Company Overview
10.3.2. Liquid Biopsy Portfolio
10.4. GeneCast Biotechnology
10.4.1. Company Overview
10.4.2. Liquid Biopsy Portfolio
10.5. Lucene
10.5.1. Company Overview
10.5.2. Liquid Biopsy Portfolio
10.6. MedGenome
10.6.1. Company Overview
10.6.2. Liquid Biopsy Portfolio
10.7. Singlera Genomics
10.7.1. Company Overview
10.7.2. Liquid Biopsy Portfolio
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Asia-Pacific Liquid Biopsy Solutions: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Partner
11.3.5. Analysis by Type of Circulating Biomarker
11.3.6. Analysis by Type of Cancer
11.3.7. Most Active Players: Analysis by Number of Partnerships
11.3.8. Analysis by Geography
11.3.8.1. Local and International Agreements
11.3.8.2. Intercontinental and Intracontinental Agreements
12. FUNDING AND INVESTMENTS
12.1. Chapter Overview
12.2. Funding Models
12.3. Asia-Pacific Liquid Biopsy Solutions: Funding and Investments
12.3.1. Analysis by Year of Funding
12.3.1.1. Cumulative Year-wise Trend of Funding Instances
12.3.1.2. Cumulative Year-wise Trend of Amount Invested
12.3.2. Analysis by Type of Funding
12.3.2.1. Analysis by Funding Instances
12.3.2.2. Analysis of Amount Invested by Year and Type of Funding
12.3.3. Analysis by Year and Type of Funding
12.3.4. Analysis by Type of Circulating Biomarker
12.3.5. Analysis by Type of Cancer
12.3.6. Analysis by Application Area
12.3.7. Most Active Players: Analysis by Number of Funding Instances
12.3.8. Most Active Players: Analysis by Amount Raised
12.3.9. Leading Investors by Number of Funding Instances
12.3.10. Analysis by Geography
13. BIG PHARMA INITIATIVES
13.1. Chapter Overview
13.2. Asia-Pacific Liquid Biopsy: List of Initiatives Undertaken by Big Players
13.2.1. Analysis by Year of Initiative
13.2.2. Analysis by Type of Initiative
13.2.3. Analysis by Year and Type of Initiative
13.2.4. Analysis of Big Pharma Players by Number of Initiatives
13.2.5. Analysis by Type of Partnership
13.2.6. Analysis of Big Pharma Player by Type of Initiative
13.2.7. Analysis of Big Pharma Player by Year of Initiative
13.2.8. Big Pharma Initiatives Summary
14. KEY ACQUISITION TARGETS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Scoring Criteria and Key Assumptions
14.4. Potential Acquisition Targets: Asia-Pacific Liquid Biopsy Solution Providers
14.5. Concluding Remarks
15. CASE STUDY: OTHER NON-INVASIVE CANCER DIAGNOSTICS
15.1. Chapter Overview
15.2. Non-Blood-based Biomarker Detection Tests
15.3. Fecal Occult Blood Test (FOBT) and Fecal Immunochemical Tests (FIT)
15.4. Pigmented Lesion Assays
15.5. Stool DNA (sDNA)-based Tests
15.6. Volatile Organic Compound (VOC) Detection Tests
15.7. List of Other Non-Invasive Cancer Diagnostics
16. MARKET IMPACT ANALYSIS
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17. ASIA-PACIFIC LIQUID BIOPSY MARKET
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Asia-Pacific Liquid Biopsy Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentations
18. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TYPE OF TECHNOLOGY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Asia-Pacific Liquid Biopsy Market: Distribution by Type of Technology
18.3.1. Asia-Pacific Liquid Biopsy Market for Next Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.2. Asia-Pacific Liquid Biopsy Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation
19. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Asia-Pacific Liquid Biopsy Market: Distribution By Type of Sample
19.3.1. Asia-Pacific Liquid Biopsy Market for Blood, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.2. Asia-Pacific Liquid Biopsy Market for Other Samples, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation
20. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Asia-Pacific Liquid Biopsy Market: Distribution By Type of Circulating Biomarker
20.3.1. Asia-Pacific Liquid Biopsy Market for Circulating Tumor DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.2. Asia-Pacific Liquid Biopsy Market for Cell Free DNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.3. Asia-Pacific Liquid Biopsy Market for Cell Free RNA, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.4. Asia-Pacific Liquid Biopsy Market for Exosomes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.3.5. Asia-Pacific Liquid Biopsy Market for Other Circulating Biomarkers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TYPE OF CANCER
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Asia-Pacific Liquid Biopsy Market: Distribution By Type of Cancer
21.3.1. Asia-Pacific Liquid Biopsy Market for Breast Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.2. Asia-Pacific Liquid Biopsy Market for Colorectal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.3. Asia-Pacific Liquid Biopsy Market for Prostate cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.4. Asia-Pacific Liquid Biopsy Market for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.5. Asia-Pacific Liquid Biopsy Market for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.6. Asia-Pacific Liquid Biopsy Market for Melanoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.7. Asia-Pacific Liquid Biopsy Market for Thyroid Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.8. Asia-Pacific Liquid Biopsy Market for Gastric Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.9. Asia-Pacific Liquid Biopsy Market for Head and Neck Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.10. Asia-Pacific Liquid Biopsy Market for Leukemia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.11. Asia-Pacific Liquid Biopsy Market for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.12. Asia-Pacific Liquid Biopsy Market for Liver Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.13. Asia-Pacific Liquid Biopsy Market for Cervical Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.14. Asia-Pacific Liquid Biopsy Market for Ovarian Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.15. Asia-Pacific Liquid Biopsy Market for Esophagus Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.16. Asia-Pacific Liquid Biopsy Market for Pancreatic Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.17. Asia-Pacific Liquid Biopsy Market for Nasopharyngeal cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.3.18. Asia-Pacific Liquid Biopsy Market for Sarcoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation
22. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Asia-Pacific Liquid Biopsy Market: Distribution By Application Area
22.3.1. Asia-Pacific Liquid Biopsy Market for Early Diagnosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.3.2. Asia-Pacific Liquid Biopsy Market for Patient Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.3.3. Asia-Pacific Liquid Biopsy Market for Recurrence Monitoring, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END-USER
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Asia-Pacific Liquid Biopsy Market: Distribution by End-user
23.3.1. Asia-Pacific Liquid Biopsy Market for Hospitals / Laboratories, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.3.2. Asia-Pacific Liquid Biopsy Market for Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.3.3. Asia-Pacific Liquid Biopsy Market for Other End-users, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation
24. CONCLUDING REMARKS
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Company A
25.2.1. Interview Transcript: Chairman
25.3. Company B
25.3.1. Interview Transcript: Founder and Chief Executive Officer
25.4. Company C
25.4.1. Interview Transcript: Chief Executive Officer
25.5. Company D
25.5.1. Interview Transcript: Founder, President and Chief Technology Officer
25.6. Company E
25.6.1. Interview Transcript: Chief Operating Officer and Co-Founder
25.7. Company F
25.7.1. Interview Transcript: Chief Medical Officer
25.8. Company G
25.8.1. Interview Transcript: Chief Scientific Officer
25.9. Company H
25.9.1. Interview Transcript: Founder and Medical Director
25.10. Company I
25.10.1. Interview Transcript: Founder
25.11. Company J
25.11.1. Interview Transcript: Innovation Director
25.12. Company K
25.12.1. Interview Transcript: Director
25.13. Company L
25.13.1. Interview Transcript: Former Chief Executive Officer and Co-founder
25.14. Company M
25.14.1. Interview Transcript: Former Chief Executive Officer
25.15. Company N
25.15.1. Interview Transcript: Former Founder
25.16. Company O
25.16.1. Interview Transcript: Former Marketing Director
25.17. Company P
25.17.1. Interview Transcript: Former Strategic Technology Advisor
25.18. Company Q
25.18.1. Interview Transcript: Former Sales and Marketing Manager
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS